Adap­ti­m­mune shares boost­ed by new signs of suc­cess with TCR cell ther­a­py

One of the big biotech stock movers Thurs­day was Adap­ti­m­mune, a UK-based biotech that saw its shares gy­rate up about 25% af­ter the com­pa­ny tout­ed fresh ev­i­dence that its TCR cell ther­a­py tech showed ear­ly signs of work­ing in a sec­ond sol­id tu­mor in­di­ca­tion.

In what’s be­come a rou­tine prac­tice in im­muno-on­col­o­gy, Adap­ti­m­mune $ADAP made hay from the first glimpse of da­ta from the first four pa­tients treat­ed with its NY-ESO SPEAR T-cells for myx­oid/round cell li­posar­co­ma, or MR­CLS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER